Krsnaa DiagnosticsNSE:KRSNAA +1.26%71 ROE % is 17.02% as of Mar. 2026, which is 70% above its 10-year median of 10.03. GuruFocus rates NSE:KRSNAA with a GF Score™ of 71/100 and a GF Value™ of ₹899.38 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Krsnaa Diagnostics ranks better than 77.72% on this metric.
The historical rank and industry rank for Krsnaa Diagnostics's ROE % or its related term are showing as below:
NSE:KRSNAA'
s ROE % Range Over the Past 10 Years
Min: 7.34 Med: 10.03 Max: 1060.13
Current: 10.92
During the past 8 years, Krsnaa Diagnostics's highest ROE % was 1,060.13%. The lowest was 7.34%. And the median was 10.03%.
NSE:KRSNAA's ROE % is ranked better than 77.72% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.31
vs NSE:KRSNAA: 10.92
Krsnaa Diagnostics (NSE:KRSNAA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Krsnaa Diagnostics ROE % Related Terms
Krsnaa Diagnostics ROE % Historical Data
* Premium members only.
The historical data trend for Krsnaa Diagnostics's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Krsnaa Diagnostics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krsnaa Diagnostics ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Krsnaa Diagnostics's ROE % distribution charts can be found below:
* The bar in red indicates where Krsnaa Diagnostics's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Krsnaa Diagnostics (NSE:KRSNAA) has a ROE % of 17.02% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Krsnaa Diagnostics and its competitors. This is 70% above median its historical median of 10.03. Over the past decade, Krsnaa Diagnostics' ROE % has ranged from 7.34 to 1,060.13. According to the industry distribution chart, Krsnaa Diagnostics ranks #45 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 22.3%.
Is Krsnaa Diagnostics' ROE % too high?
Krsnaa Diagnostics' current ROE % of 17.02% is 70% above median its 10-year median of 10.03. Over the past 10 years, this metric has ranged from a low of 7.34 to a high of 1,060.13. Based on the distribution chart, Krsnaa Diagnostics ranks #45 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Krsnaa Diagnostics has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Krsnaa Diagnostics' ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Krsnaa Diagnostics ranks #45 out of 202 companies for ROE %. This places Krsnaa Diagnostics in the top 22% of its industry — outperforming the majority of peers. Historically, Krsnaa Diagnostics' own ROE % has ranged from 7.34 to 1,060.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Krsnaa Diagnostics and its competitors. Krsnaa Diagnostics's current ROE % is 17.02%, which is 70% above median its own 10-year median of 10.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krsnaa Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Krsnaa Diagnostics (NSE:KRSNAA) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹899.38, compared to a current price of ₹543.80 — trading 39.5% below its estimated fair value. The current ROE % is 17.02%, which is 70% above median its 10-year median of 10.03. Krsnaa Diagnostics' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Krsnaa Diagnostics (NSE:KRSNAA), the current ROE % is 17.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krsnaa Diagnostics (NSE:KRSNAA) Overvalued in 2026?
Based on GuruFocus' analysis, Krsnaa Diagnostics stock appears to be undervalued.
The current stock price of ₹543.80 is trading 39.5% below its estimated GF Value™ of ₹899.38.
GuruFocus considers Krsnaa Diagnostics to be Significantly Undervalued.
Key valuation signals for NSE:KRSNAA:
ROE %: 17.02% (70% above median its 10-year median of 10.03)
GF Value™: ₹899.38 vs. price of ₹543.80 (39.5% below fair value)
No single metric tells the full story. See the NSE:KRSNAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krsnaa Diagnostics Ltd is a diagnostic services provider, both in Radiology and Pathology. It offers a wide range of diagnostic services such as imaging/radiology services, routine clinical laboratory tests, pathology, and tele-radiology services to private and public hospitals, medical colleges, and community health centres. The company's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, tele-reporting services, and all types of Blood and Urine investigations.
71GF Score
Get the complete analysis for NSE:KRSNAA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KRSNAA has been successfully added to your 
